What question did this study set out to answer?

The research aims to evaluate whether biomarker-informed therapy decisions improve clinical outcomes in inflammatory bowel disease patients receiving anti-TNF therapy.

January 23, 2026Journal of Crohn s and Colitis

OP13Biomarker-informed therapy guidance improved clinical outcomes of anti-tumour necrosis factor treatment in patients with inflammatory bowel disease in a multi-centre, randomized, controlled, open-label, prospective clinical trial (GUIDE-IBD)

View Full Paper

Ask AI

Bookmark

Authors

FTFlorian TranKiel University KAKonrad AdenFachhochschule Kiel JBJ P BernardesKiel University

Discussion

Member takes

Implication

Randomized controlled trial examines biomarker-informed therapy guidance, improving clinical outcomes in IBD, suggesting enhanced treatment strategies.

Key Points

The research aims to evaluate whether biomarker-informed therapy decisions improve clinical outcomes in inflammatory bowel disease patients receiving anti-TNF therapy.
Conducted a randomized controlled trial across three German university hospitals.
Involved adults with Crohn’s disease or ulcerative colitis initiating infliximab therapy.
Compared molecular medicine care with standard best care using real-time biomarker assessments and pharmacometrics modeling.
At week 52, comprehensive disease control was achieved more frequently in the molecular medicine care group (43%) compared to best care (23%).
The odds ratio for the benefit of molecular medicine care was 2.53, showing significant improvement (p = 0.031).
Secondary outcomes favored the molecular medicine care, particularly in steroid-free remission.

Cite This Study

Tran et al. (2026) studied this question.

synapsesocial.com/papers/69730fc4c8125b09b0d1f7e9 https://doi.org/10.1093/ecco-jcc/jjaf231.013

View Full Paper

Ask AI

Bookmark

Implication

Randomized controlled trial examines biomarker-informed therapy guidance, improving clinical outcomes in IBD, suggesting enhanced treatment strategies.

OP13Biomarker-informed therapy guidance improved clinical outcomes of anti-tumour necrosis factor treatment in patients with inflammatory bowel disease in a multi-centre, randomized, controlled, open-label, prospective clinical trial (GUIDE-IBD)

Discussion

Member takes

Implication

Key Points

Cite This Study

OP13Biomarker-informed therapy guidance improved clinical outcomes of anti-tumour necrosis factor treatment in patients with inflammatory bowel disease in a multi-centre, randomized, controlled, open-label, prospective clinical trial (GUIDE-IBD)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider